Clinical Trial Update: Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma [Phase 1]

View source ↗

Summary

This clinical trial update notes a Phase I study of cosibelimab in combination with balixafortide for metastatic pancreatic ductal adenocarcinoma, which is not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Balixafortide (balixafortide)
• cosibelimab (cosibelimab)

Snippet

Sponsor: Arsen Osipov | Conditions: Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 | Status: NOT_YET_RECRUITING